OVERVIEW

Cardiovascular medicine is approaching a pivotal turning point, in which therapies introduced are shifting from those based on phenotype to those that treat the root underlying mechanism (endotype) and, more recently, the genetic cause (genotype). Such changes promise more effective therapies that promise to cure diseases instead of simply slowing down their progress.  For this promise to be fulfilled, it will require more than developing new therapeutics -fundamental changes will need to occur in clinical practice, including how we identify at-risk patients, predict their disease trajectory, and monitor the benefit and side effects of new therapeutics.

TARGET AUDIENCE

LEARNING OBJECTIVES

• Provide an Overview of the Changing Landscape of Cardiovascular Diagnostics and Therapeutics
• Discuss cutting-edge preclinical science in cardiovascular biology.
• Review advances in translational biology, including new biomarker technology.
• Provide a synopsis of current and pending clinical trials in precision cardiology.

ACCREDITATION

There is No CME for this activity. 

For more information please visit the official event page.